Dupilumab: as the comparator
26 studies: what is tested is compared with it. Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) CoformulationNot yet recruitingNCT07919899Phase 3Report a problem
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe EczemaRecruitingNCT07783425Phase 3Report a problem
- A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic DermatitisRecruitingNCT07754786Phase 3Report a problem
- A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic DermatitisRecruitingNCT07399067Phase 2Report a problem
- A Phase III Study of GS101 Injection to Dupixent®RecruitingNCT07386743Phase 3Report a problem
- A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.RecruitingNCT07358156Phase 1Report a problem
- A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male SubjectsNot yet recruitingNCT07334496Phase 1Report a problem
- A Phase Ⅲ Comparative Study of QL2108 to Dupixent®Not yet recruitingNCT06884891Phase 3Report a problem
- A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT05601882Phase 3Results postedReport a problem
- A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe ADCompletedNCT05470114Phase 2Results postedReport a problem
- A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic DermatitisTerminatedNCT04791319Phase 2Results postedReport a problem
- Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT04345367Phase 3Results postedReport a problem
- A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT03738397Phase 3Results postedReport a problem
- Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical TherapyCompletedNCT03720470Phase 3Results postedReport a problem
- Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma ParticipantsCompletedNCT03387852Phase 2Results postedReport a problem
- A Phase I Study of 9MW4113 Injection Versus Dupixent®Active, not recruitingNCT07791342Phase 1Report a problem
- A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese VolunteersActive, not recruitingNCT07502534Phase 1Report a problem
- A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous InjectionCompletedNCT07411755Phase 1Report a problem
- A Study to Evaluate Efficacy and Safety of IBI356 in Participants With Moderate to Severe Atopic DermatitisTerminatedNCT07330934Phase 2Report a problem
- An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT07027527Phase 1Report a problem
- A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)TerminatedNCT06881251Phase 2Report a problem
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistaminesActive, not recruitingNCT06868212Phase 3Report a problem
- A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®CompletedNCT06614907Phase 1Report a problem
- A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic DermatitisActive, not recruitingNCT06461897Phase 3Report a problem
- A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to DupilumabActive, not recruitingNCT06389136Phase 3Report a problem
- A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis PatientsCompletedNCT06193434Phase 1Report a problem